Biolase (BIOL)
(Delayed Data from NSDQ)
$0.15 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.15 0.00 (1.35%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIOL 0.15 0.00(0.00%)
Will BIOL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BIOL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIOL
Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities
BIOL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BIOL
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
Biolase’s Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating
12 Health Care Stocks Moving In Friday's Intraday Session
Dow Dips 200 Points; Nike Shares Fall After Q3 Results